AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for B-Cell Non-Hodgkin Lymphoma-Recurrent

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFYยฎ+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma NCT05645107Phase 362 sites๐Ÿ“ Bullhead City๐Ÿ“ Huntington Park๐Ÿ“ St. Petersburg Grifols Therapeutics LLC ยท Tests: Xembify, Placebo Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites๐Ÿ“ Minneapolis๐Ÿ“ Columbus๐Ÿ“ Richmond Yazeed Sawalha ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. NCT04915248Phase 218 sites๐Ÿ“ Ancona๐Ÿ“ Aviano๐Ÿ“ Florence Fondazione Italiana Linfomi - ETS ยท Tests: Daratumumab, Bortezomib, Dexamethasone CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19x22 CAR T UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies NCT06743503Phase 12 sites๐Ÿ“ Nanjing๐Ÿ“ Tianjin Nanjing IASO Biotechnology Co., Ltd. ยท Tests: UB-VV400, Rapamycin Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site๐Ÿ“ Seattle University of Washington ยท Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therโ€ฆ Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033Phase 253 sites๐Ÿ“ Anchorage๐Ÿ“ Clovis๐Ÿ“ Fullerton Hoffmann-La Roche ยท Tests: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab NCT06287229Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma NCT07126236Phase 219 sites๐Ÿ“ Seville๐Ÿ“ Zaragoza๐Ÿ“ Palma de Mallorca Grupo Espaรฑol de Linfomas y Transplante Autรณlogo de Mรฉdula โ€ฆ ยท Tests: Epcoritamab, Epcoritamab, tafasitamab and lenalidomide A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma NCT05533775Phase 1, Phase 230 sites๐Ÿ“ Birmingham๐Ÿ“ Oakland๐Ÿ“ Oakland Hoffmann-La Roche ยท Tests: Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites๐Ÿ“ Tucson๐Ÿ“ Tucson๐Ÿ“ Los Angeles National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL NCT05370430Phase 16 sites๐Ÿ“ Duarte๐Ÿ“ Stanford๐Ÿ“ Kansas City PeproMene Bio, Inc. ยท Tests: BAFFR-CAR T cells A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas NCT05685173Phase 120 sites๐Ÿ“ Duarte๐Ÿ“ Santa Monica๐Ÿ“ Louisville Regeneron Pharmaceuticals ยท Tests: Odronextamab, REGN5837 CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma NCT06209619Phase 11 site๐Ÿ“ Columbus Nathan Denlinger ยท Tests: Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto๐Ÿ“ Aurora Autolus Limited ยท Tests: AUTO1 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site๐Ÿ“ Ann Arbor University of Michigan Rogel Cancer Center ยท Tests: Biospecimen Collection, Pomalidomide Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas NCT07883135Phase 21 site๐Ÿ“ Moscow National Research Center for Hematology, Russia ยท Tests: Glofitamab, Epcoritamab, Polatuzumab Vedotin, Gemcitabine & oxaliplatin, Obinutuzumab Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: biologic sample preservation procedure, cytology specimen collection procedure Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia NCT03418038Phase 24 sites๐Ÿ“ Mankato๐Ÿ“ Rochester๐Ÿ“ Eau Claire Mayo Clinic ยท Tests: Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250Phase 1, Phase 231 sites๐Ÿ“ La Jolla๐Ÿ“ Boston๐Ÿ“ Rochester AstraZeneca ยท Tests: AZD5492 A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies NCT06634589Phase 1, Phase 249 sites๐Ÿ“ Phoenix๐Ÿ“ Los Angeles๐Ÿ“ Jacksonville BeOne Medicines ยท Tests: Tacabrutideg, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma NCT07198230n/a1 site๐Ÿ“ Fuzhou Ting YANG UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL NCT04544592Phase 1, Phase 21 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ยฑ ASCT in R/R Aggressive B-Cell Lymphoma NCT06996132Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: Glofitamab, Chimeric Antigen Receptor T Cells (CAR-T) A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma NCT07609030NA1 site๐Ÿ“ Columbus Ohio State University Comprehensive Cancer Center ยท Tests: Biospecimen Collection, Cognitive Intervention, Electronic Health Record Review, Survey Administration Novel Allogenic CD19-targeting CAR-ฮณฮดT Cell Therapy (QH103E) in r/r NHL NCT06838832Phase 1, Phase 21 site๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: Allogenic CD19-CAR-ฮณฮดT cell, Fludarabine, Cyclophosphamide Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma NCT07283679Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: ONC-PluReceptor NK cells Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy